phase I a study of LBL-007 monotherapy in patients with later-stage solid tumors
Latest Information Update: 08 Jul 2023
Price :
$35 *
At a glance
- Drugs LBL-007 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 08 Jul 2023 New trial record
- 30 Jun 2023 According to a Chime Biologics media release, results from this study were published in ASCO 2021 (Abstract 2523).